Capricor Therapeutics (CAPR) EBT (2010 - 2026)

Capricor Therapeutics' EBT history runs 17 years deep, the most recent figure standing at -$33.9 million for Q1 2026.

• In Q1 2026, EBT fell 39.15% year-over-year to -$33.9 million; the TTM figure through Mar 2026 stood at -$111.6 million (down 434.04% YoY), while the FY2025 annual figure was -$105.0 million, down 159.58% from the prior year.
• EBT was -$33.9 million for Q1 2026 at Capricor Therapeutics, down from -$27.1 million in the prior quarter.
• In the past five years, EBT ranged from a high of $27.1 million in Q4 2024 to a low of -$33.9 million in Q1 2026.
• Historically, EBT has averaged -$11.4 million across 5 years, with a median of -$7.8 million in 2022.
• The sharpest annual moves came in 2024 and 2025: EBT jumped 3363.3% in 2024, then sank 200.29% in 2025.
• A 5-year view of EBT shows it stood at -$7.7 million in 2022, then surged by 89.21% to -$829093.0 in 2023, then surged by 3363.3% to $27.1 million in 2024, then tumbled by 200.29% to -$27.1 million in 2025, then fell by 25.08% to -$33.9 million in 2026.
• The last three EBT figures came in at -$33.9 million (Q1 2026), -$27.1 million (Q4 2025), and -$24.6 million (Q3 2025), per Business Quant data.